ACH. Arch Biopartners Inc.

Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida

Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida
EN
07/10/2020

Underlying

ACH.Arch Biopartners Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arch Biopartners Inc.

 PRESS RELEASE
Free
ACH. Arch Biopartner...

Arch Strengthens its Position as a Leading Kidney Therapeutics Company...

Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD) Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated in CKD, discovered in pre-clinical studies led by Dr. Justin Chun The Company has filed both composition and method of use patents relating to the CKD platform. The Arch CKD program will be led by Dr. Justin Chun,...

September 17, 2025 1 EN
 PRESS RELEASE
Free
ACH. Arch Biopartner...

Arch Biopartners Announces First Patient Successfully Dosed at Toronto...

Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury First patient successfully completes dosing at Toronto General HospitalSt. Michael’s Hospital is expected to be the next Canadian clinical site activatedArch is looking for additional clinical sites in North America to join the trial TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) --  (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the first patient has successfully completed d...

August 6, 2025 1 EN
 PRESS RELEASE
Free
ACH. Arch Biopartner...

Arch Biopartners Announces Start of Patient Recruitment in Phase II PO...

Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI) TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled “Prevention Of NephroToxin Induced Acute Kidney Injury with Cilastatin” (PONTIAK) has commenced patient recruitment at its primary clinical sites in Alberta, Canada. The Phase II PONTIAK study aims to evaluate the efficacy of cilastatin in preventing AKI associated with nephrotoxic pha...

July 22, 2025 1 EN
 PRESS RELEASE
Free
ACH. Arch Biopartner...

Arch Biopartners Announces Toronto General Hospital Ethics Board Appro...

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research Ethics Board has granted approval for Toronto General Hospital to participate in the Company’s ongoing for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With this ethics approval in place a...

April 22, 2025 1 EN
 PRESS RELEASE
Free
ACH. Arch Biopartner...

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONT...

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique off-target effects that block toxin uptake into the kidney tissueArch continues to perform a Phase II trial for LSALT peptide targeting cardiac surgery-associated-AKI Drug toxins and CS-AKI account for up to 50% of all AKI occurring in hospitals, for whic...

August 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch